Whatever Happened to the Epoxyeicosatrienoic Acid-Like Endothelium-Derived Hyperpolarizing Factor? The Identification of Novel Classes of Lipid Mediators and Their Role in Vascular Homeostasis

Antioxidants and Redox Signaling

Volumn 22, Issue 14, 2015, Pages 1273-1292

  Frömel, Timo ^a   Fleming, Ingrid ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CYTOCHROME P450; DOCOSAHEXAENOIC ACID; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EPOXIDE; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; G PROTEIN COUPLED RECEPTOR; ICOSAPENTAENOIC ACID; PHOSPHOLIPID; BIOLOGICAL FACTOR; DIHOMO GAMMA LINOLENIC ACID; ENDOTHELIUM-DEPENDENT HYPERPOLARIZATION FACTOR; OMEGA 3 FATTY ACID;

ANGIOGENESIS; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BIOLOGICAL ACTIVITY; CELL COMMUNICATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SUBSTRATE; FATTY ACID METABOLISM; GAP JUNCTION; HOMEOSTASIS; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASCULAR HOMEOSTASIS; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; METABOLISM; SIGNAL TRANSDUCTION;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; BIOLOGICAL FACTORS; CYTOCHROME P-450 ENZYME SYSTEM; FATTY ACIDS, OMEGA-3; HOMEOSTASIS; HUMANS; SIGNAL TRANSDUCTION;

EID: 84928558655     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.6150     Document Type: Review

References (199)

1. Agbor LN, Walsh MT, Boberg JR, and Walker MK. Elevated blood pressure in cytochrome P4501A1 knockout mice is associated with reduced vasodilation to omega-3 polyunsaturated fatty acids. Toxicol Appl Pharmacol 264: 351-360, 2012.
2. Ai D, Fu Y, Guo D, Tanaka H, Wang N, Tang C, Hammock BD, Shyy JYJ, and Zhu Y. Angiotensin II upregulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci U S A 104: 9018-9023, 2007.
3. Alvarez J, Montero M, and García-Sancho J. Cytochrome P450 may link intracellular Ca2+ stores with plasma membrane Ca2+ influx. Biochem J 274: 193-197, 1991.
4. Arnold C, Markovic M, Blossey K, Wallukat G, Fischer R, Dechend R, Konkel A, von SC, Luft FC, Muller DN, Rothe M, and Schunck WH. Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of ω-3 fatty acids. J Biol Chem 285: 32723-32733, 2010.
5. Arterburn LM, Hall EB, and Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 83: 1467S-1476S, 2006.
6. Astarita G, McKenzie JH, Wang B, Strassburg K, Doneanu A, Johnson J, Baker A, Hankemeier T, Murphy J, Vreeken RJ, Langridge J, and Kang JX. A protective lipidomic biosignature associated with a balanced omega-6/omega-3 ratio in fat-1 transgenic mice. PLoS One 9: e96221, 2014.
7. This reference has been deleted.
8. Augood C, Chakravarthy U, Young I, Vioque J, de Jong PT, Bentham G, Rahu M, Seland J, Soubrane G, Tomazzoli L, Topouzis F, Vingerling JR, and Fletcher AE. Oily fish consumption, dietary docosahexaenoic acid and eicosapentaenoic acid intakes, and associations with neovascular age-related macular degeneration. Am J Clin Nutr 88: 398-406, 2008.
9. Bagga D, Wang L, Farias-Eisner R, Glaspy JA, and Reddy ST. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A 100: 1751-1756, 2003.
10. Barbosa-Sicard E, Frömel T, Keserü B, Brandes RP, Morisseau C, Hammock BD, Braun T, Krüger M, and Fleming I. Inhibition of the soluble epoxide hydrolase by tyrosine nitration. J Biol Chem 284: 28156-28163, 2009.
11. Barbosa-Sicard E, Markovic M, Honeck H, Christ B, Muller DN, and Schunck WH. Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily. Biochem Biophys Res Commun 329: 1275-1281, 2005.
12. Bellien J, Iacob M, Gutierrez L, Isabelle M, Lahary A, Thuillez C, and Joannides R. Crucial role of NO and endothelium-derived hyperpolarizing factor in human sustained conduit artery flow-mediated dilatation. Hypertension 48: 1088-1094, 2006.
13. Bellien J, Joannides R, Iacob M, Arnaud P, and Thuillez C. Evidence for a basal release of a cytochrome-related endothelium-derived hyperpolarizing factor in the radial artery in humans. Am J Physiol Heart Circ Physiol 290: H1347-H1352, 2006.
14. Blasbalg TL, Hibbeln JR, Ramsden CE, Majchrzak SF, and Rawlings RR. Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am J Clin Nutr 93: 950-962, 2011.
15. Boettcher M and de Wit C. Distinct endothelium-derived hyperpolarizing factors emerge in vitro and in vivo and are mediated in part via connexin 40-dependent myoendothelial coupling. Hypertension 57: 802-808, 2011.
16. Bolz SS, Fisslthaler B, Pieperhoff S, de Wit C, Fleming I, Busse R, and Pohl U. Antisense oligonucleotides against cytochrome P450 2C8 attenuate EDHF-mediated Ca2+changes and dilation in isolated resistance arteries. FASEB J 14: 255-260, 2000.
17. Bui P, Solaimani P, Wu X, and Hankinson O. 2,3,7,8-Tetrachlorodibenzo-p-dioxin treatment alters eicosanoid levels in several organs of the mouse in an aryl hydrocarbon receptor-dependent fashion. Toxicol Appl Pharmacol 259: 143-151, 2012.
18. Burns KD, Capdevila J, Wei S, Breyer MD, Homma T, and Harris RC. Role of cytochrome P-450 epoxygenase metabolites in EGF signaling in renal proximal tubule. Am J Physiol 269: C831-C840, 1995.
19. Burns RN and Moniri NH. Agonism with the omega-3 fatty acids alpha-linolenic acid and docosahexaenoic acid mediates phosphorylation of both the short and long isoforms of the human GPR120 receptor. Biochem Biophys Res Commun 396: 1030-1035, 2010.
20. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, and Weston AH. EDHF: bringing the concepts together. Trends Pharmacol Sci 23: 374-380, 2002.
21. Bystrom J, Wray JA, Sugden MC, Holness MJ, Swales KE, Warner TD, Edin ML, Zeldin DC, Gilroy DW, and Bishop-Bailey D. Endogenous epoxygenases are modulators of monocyte/macrophage activity. PLoS One 6: e26591, 2011.
22. Calviello G, Su HM, Weylandt KH, Fasano E, Serini S, and Cittadini A. Experimental evidence of omega-3 polyunsaturated fatty acid modulation of inflammatory cytokines and bioactive lipid mediators: their potential role in inflammatory, neurodegenerative, and neoplastic diseases. Biomed Res Int 2013: 743171, 2013.
23. Campbell WB, Gebremedhin D, Pratt PF, and Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78: 415-423, 1996.
24. Capdevila JH, Kishore V, Dishman E, Blair IA, and Falck JR. A novel pool of rat liver inositol and ethanolamine phospholipids contains epoxyeicosatrienoic acids (EETs). Biochem Biophys Res Commun 146: 638-644, 1987.
25. Carolina BJ, Eduardo S, Luiz FMP, Augusto S, Francielle B, Fernanda TDR, Simone H, Francisco ABD, Juan JL, Marcio NC, and Nelson JLD. Linoleic and α-linolenic fatty acid consumption over three generations exert cumulative regulation of hepatic expression of genes related to lipid metabolism. Genes Nutr 9: 405, 2014.
26. Chang CL, Torrejon C, Jung UJ, Graf K, and Deckelbaum RJ. Incremental replacement of saturated fats by n-3 fatty acids in high-fat, high-cholesterol diets reduces elevated plasma lipid levels and arterial lipoprotein lipase, macrophages and atherosclerosis in LDLR-/- mice. Atherosclerosis 234: 401-409, 2014.
27. Chen JK, Falck JR, Reddy KM, Capdevila J, and Harris RC. Epoxyeicosatrienoic acids and their sulfonimide derivatives stimulate tyrosine phosphorylation and induce mitogenesis in renal epithelial cells. J Biol Chem 273: 29254-29261, 1998.
28. Chen JK, Wang D-W, Falck JR, Capdevila J, and Harris RC. Transfection of an active cytochrome P450 arachidonic acid epoxygenase indicates that 14,15-epoxyeicosatrienoic acid functions as an intracellular messenger in response to epidermal growth factor. J Biol Chem 274: 4764-4769, 1999.
29. Chen J-K, Capdevila J, and Harris RC. Heparin-binding EGF-like growth factor mediates the biological effects of P450 arachidonate epoxygenase metabolites in epithelial cells. Proc Natl Acad Sci U S A 99: 6029-6034, 2002.
30. Chen L, Ackerman R, and Guo AM. 20-HETE in neovascularization. Prostaglandins Other Lipid Mediat 98: 63-68, 2012.
31. Cheranov SY, Karpurapu M, Wang D, Zhang B, Venema RC, and Rao GN. An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis. Blood 111: 5581-5591, 2008.
32. Chiang N, Fredman G, Backhed F, Oh SF, Vickery T, Schmidt BA, and Serhan CN. Infection regulates proresolving mediators that lower antibiotic requirements. Nature 484: 524-528, 2012.
33. Connor KM, Sangiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, Hong S, Pravda EA, Majchrzak S, Carper D, Hellstrom A, Kang JX, Chew EY, Salem N, Jr., Serhan CN, and Smith LE. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 13: 868-873, 2007.
34. Cui PH, Petrovic N, and Murray M. The omega-3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 down-regulation. Br J Pharmacol 162: 1143-1155, 2011.
35. Ding Y, Frömel T, Popp R, Falck JR, Schunck WH, and Fleming I. The biological actions of 11,12-epoxyeicosatrienoic acid in endothelial cells are specific to the R/S-enantiomer and require the Gs protein. J Pharmacol Exp Ther 350: 14-21, 2014.
36. Doulias PT, Greene JL, Greco TM, Tenopoulou M, Seeholzer SH, Dunbrack RL, and Ischiropoulos H. Structural profiling of endogenous S-nitrosocysteine residues reveals unique features that accommodate diverse mechanisms for protein S-nitrosylation. Proc Natl Acad Sci U S A 107: 16958-16963, 2010.
37. Dunworth WP, Cardona-Costa J, Bozkulak EC, Kim JD, Meadows S, Fischer JC, Wang Y, Cleaver O, Qyang Y, Ober EA, and Jin SW. Bone morphogenetic protein 2 signaling negatively modulates lymphatic development in vertebrate embryos. Circ Res 114: 56-66, 2014.
38. Egert S and Stehle P. Impact of n-3 fatty acids on endothelial function: results from human interventions studies. Curr Opin Clin Nutr Metab Care 14: 121-131, 2011.
39. Falck JR, Krishna UM, Reddy YK, Kumar PS, Reddy KM, Hittner SB, Deeter C, Sharma KK, Gauthier KM, and Campbell WB. Comparison of vasodilatory properties of 14,15-EET analogs: structural requirements for dilation. Am J Physiol Heart Circ Physiol 284: H337-H349, 2003.
40. Fang X, Hu S, Watanabe T, Weintraub NL, Snyder GD, Yao J, Liu Y, Shyy JYJ, Hammock BD, and Spector AA. Activation of peroxisome proliferator-activated receptor α by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther 314: 260-270, 2005.
41. Fares H, Lavie CJ, Dinicolantonio JJ, O'Keefe JH, and Milani RV. Omega-3 fatty acids: a growing ocean of choices. Curr Atheroscler Rep 16: 389, 2014.
42. Fer M, Dreano Y, Lucas D, Corcos L, Salaun JP, Berthou F, and Amet Y. Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450. Arch Biochem Biophys 471: 116-125, 2008.
43. Fischer D, Landmesser U, Spiekermann S, Hilfiker-Kleiner D, Hospely M, Muller M, Busse R, Fleming I, and Drexler H. Cytochrome P450 2C9 is involved in flowdependent vasodilation of peripheral conduit arteries in healthy subjects and in patients with chronic heart failure. Eur J Heart Fail 9: 770-775, 2007.
44. Fischer R, Konkel A, Mehling H, Blossey K, Gapelyuk A, Wessel N, von Schacky C, Dechend R, Muller DN, Rothe M, Luft FC, Weylandt K, and Schunck WH. Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway. J Lipid Res 55: 1150-1164, 2014.
45. Fisslthaler B, Hinsch N, Chataigneau T, Popp R, Kiss L, Busse R, and Fleming I. Nifedipine increases cytochrome P4502C expression and EDHF-mediated responses in coronary arteries. Hypertension 36: 270-275, 2000.
46. Fisslthaler B, Michaelis UR, Randriamboavonjy V, Busse R, and Fleming I. Cytochrome P450 epoxygenases and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression. Biochim Biophys Acta 1619: 332-339, 2003.
47. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, and Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401: 493-497, 1999.
48. Fleming I. Cytochrome P450 and vascular homeostasis. Circ Res 89: 753-762, 2001.
49. Fleming I, Fisslthaler B, Michaelis UR, Kiss L, Popp R, and Busse R. The coronary endothelium-derived hyperpolarizing factor (EDHF) stimulates multiple signalling pathways and proliferation in vascular cells. Pflugers Arch 442: 511-518, 2001.
50. Fleming I, Michaelis UR, Bredenkötter D, Fisslthaler B, Dehghani F, Brandes RP, and Busse R. Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88: 44-51, 2001.
51. Fleming I, Rueben A, Popp R, Fisslthaler B, Schrodt S, Sander A, Haendeler J, Falck JR, Morisseau C, Hammock BD, and Busse R. Epoxyeicosatrienoic acids regulate Trp channel dependent Ca2+ signaling and hyperpolarization in endothelial cells. Arterioscler Thromb Vasc Biol 27: 2612-2618, 2007.
52. Fliesler SJ and Anderson RE. Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res 22: 79-131, 1983.
53. Franklin MR and Hathaway LB. 2-Diethylaminoethyl-2,2-diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol. Drug Metab Dispos 36: 2539-2546, 2008.
54. Frömel T, Jungblut B, Hu J, Trouvain C, Barbosa-Sicard E, Popp R, Liebner S, Dimmeler S, Hammock BD, and Fleming I. Soluble epoxide hydrolase regulates hematopoietic progenitor cell function via generation of fatty acid diols. Proc Natl Acad Sci U S A 109: 9995-10000, 2012.
55. Frömel T, Kohlstedt K, Popp R, Yin X, Barbosa-Sicard E, Thomas AC, Liebertz R, Mayr M, and Fleming I. Cytochrome P4502S1: a novel monocyte/macrophage fatty acid epoxygenase in human atherosclerotic plaques. Basic Res Cardiol 108: 1-12, 2013.
56. Gauthier KM, Deeter C, Krishna UM, Reddy YK, Bondlela M, Falck JR, and Campbell WB. 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res 90: 1028-1036, 2002.
57. Graier WF, Simecek S, and Sturek M. Cytochrome P450 mono-oxygenase-regulated signalling of Ca2+ entry in human and bovine endothelial cells. J Physiol (Lond) 482: 259-274, 1995.
58. Harris TR and Hammock BD. Soluble epoxide hydrolase: gene structure, expression and deletion. Gene 526: 61-74, 2013.
59. Herbert SP, Huisken J, Kim TN, Feldman ME, Houseman BT, Wang RA, Shokat KM, and Stainier DY. Arterial-venous segregation by selective cell sprouting: an alternative mode of blood vessel formation. Science 326: 294-298, 2009.
60. Hercule HC, Salanova B, Essin K, Honeck H, Falck JR, Sausbier M, Ruth P, Schunck WH, Luft FC, and Gollasch M. The vasodilator 17,18-epoxyeicosatetraenoic acid targets the pore-forming BK alpha channel subunit in rodents. Exp Physiol 92: 1067-1076, 2007.
61. Hillig T, Krustrup P, Fleming I, Osada T, Saltin B, and Hellsten Y. Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans. J Physiol (Lond) 546: 307-314, 2003.
62. Honda HM, Leitinger N, Frankel M, Goldhaber JI, Natarajan R, Nadler JL, Weiss JN, and Berliner JA. Induction of monocyte binding to endothelial cells by MM-LDL: role of lipoxygenase metabolites. Arterioscler Thromb Vasc Biol 19: 680-686, 1999.
63. Hoshi T, Wissuwa B, Tian Y, Tajima N, Xu R, Bauer M, Heinemann SH, and Hou S. Omega-3 fatty acids lower blood pressure by directly activating large-conductance Ca2+-dependent K+ channels. Proc Natl Acad Sci U S A 110: 4816-4821, 2013.
64. Hu J, Popp R, Frömel T, Ehling M, Awwad K, Adams RH, Hammes HP, and Fleming I. Müller glia cells regulate Notch signaling and retinal angiogenesis via the generation of 19,20-dihydroxydocosapentaenoic acid. J Exp Med 211: 281-295, 2014.
65. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 289: F496-F503, 2005.
66. Imig JD. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev 92: 101-130, 2012.
67. Imig JD. Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function. Prostaglandins Other Lipid Mediat 104-105: 2-7, 2013.
68. Imig JD, Falck JR, Wei S, and Capdevila JH. Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilation in response to bradykinin. J Vasc Res 38: 247-255, 2001.
69. Imig JD and Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 8: 794-805, 2009.
70. Inceoglu B, Schmelzer KR, Morisseau C, Jinks SL, and Hammock BD. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat 82: 42-49, 2007.
71. Jordi M, Aleix S, Richard K, Raimon F, Núria P, Josefa G, Daiana I, Mercedes H, Emilio R, and Lluís M. Increasing long-chain n-3PUFA consumption improves small peripheral artery function in patients at intermediate-high cardiovascular risk. J Nutr Biochem 25: 642-646, 2014.
72. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, and Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15: 1751, 1996.
73. Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 277: 8755-8758, 2002.
74. Jung O, Brandes RP, Kim IH, Schweda F, Schmidt R, Hammock BD, Busse R, and Fleming I. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 45: 759-765, 2005.
75. Kang JX, Wang J, Wu L, and Kang ZB. Transgenic mice: fat-1 mice convert n-6 to n-3 fatty acids. Nature 427: 504, 2004.
76. Karara A, Dishman E, Falck JR, and Capdevila JH. Endogenous epoxyeicosatrienoyl-phospholipids. A novel class of cellular glycerolipids containing epoxidized arachidonate moieties. J Biol Chem 266: 7561-7569, 1991.
77. Keserü B, Barbosa-Sicard E, Popp R, Fisslthaler B, Dietrich A, Gudermann T, Hammock BD, Falck JR, Weissmann N, Busse R, and Fleming I. Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response. FASEB J 22: 4306-4315, 2008.
78. Keserü B, Barbosa-Sicard E, Schermuly RT, Tanaka H, Hammock BD, Weissmann N, Fisslthaler B, and Fleming I. Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition. Cardiovasc Res 85: 232-240, 2010.
79. Khojasteh S, Prabhu S, Kenny J, Halladay J, and Lu A. Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet 36: 1-16, 2011.
80. Kidd PM. Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. Altern Med Rev 12: 207-227, 2007.
81. Kim HY. Novel metabolism of docosahexaenoic acid in neural cells. J Biol Chem 282: 18661-18665, 2007.
82. Kim JD, Kang Y, Kim J, Papangeli I, Kang H, Wu J, Park H, Nadelmann E, Rockson SG, Chun HJ, and Jin SW. Essential role of apelin signaling during lymphatic development in zebrafish. Arterioscler Thromb Vasc Biol 34: 338-345, 2014.
83. Kim W, Fan YY, Barhoumi R, Smith R, McMurray DN, and Chapkin RS. n-3 polyunsaturated fatty acids suppress the localization and activation of signaling proteins at the immunological synapse in murine CD4+ T cells by affecting lipid raft formation. J Immunol 181: 6236-6243, 2008.
84. Kitson AP, Stark KD, and Duncan RE. Enzymes in brain phospholipid docosahexaenoic acid accretion: a PL-ethora of potential PL-ayers. Prostaglandins Leukot Essent Fatty Acids 87: 1-10, 2012.
85. Knapp HR and FitzGerald GA. The antihypertensive effects of fish oil. A controlled study of polyunsaturated fatty acid supplements in essential hypertension. N Engl J Med 320: 1037-1043, 1989.
86. Konkel A and Schunck WH. Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. Biochim Biophys Acta 1814: 210-222, 2011.
87. Kumar KV, Rao SM, Gayani R, Mohan IK, and Naidu MUR. Oxidant stress and essential fatty acids in patients with risk and established ARDS. Clin Chim Acta 298: 111-120, 2000.
88. Lai LH, Wang RX, Jiang WP, Yang XJ, Song JP, Li XR, and Tao G. Effects of docosahexaenoic acid on large-conductance Ca2+-activated K+ channels and voltage-dependent K+ channels in rat coronary artery smooth muscle cells. Acta Pharmacol Sin 30: 314-320, 2009.
89. Lauterbach B, Barbosa-Sicard E, Wang MH, Honeck H, Kargel E, Theuer J, Schwartzman ML, Haller H, Luft FC, Gollasch M, and Schunck WH. Cytochrome P450-dependent eicosapentaenoic acid metabolites are novel BK channel activators. Hypertension 39: 609-613, 2002.
90. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, and Iruela-Arispe ML. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130: 691-703, 2007.
91. Lee SM and An WS. Cardioprotective effects of omega-3 PUFAs in chronic kidney disease. Biomed Res Int 2013: 712949, 2013.
92. Leonard AE, Pereira SL, Sprecher H, and Huang YS. Elongation of long-chain fatty acids. Prog Lipid Res 43: 36-54, 2004.
93. Levental I, Grzybek M, and Simons K. Greasing their way: lipid modifications determine protein association with membrane rafts. Biochemistry 49: 6305-6316, 2010.
94. Liu JY, Li N, Yang J, Li N, Qiu H, Ai D, Chiamvimonvat N, Zhu Y, and Hammock BD. Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proc Natl Acad Sci U S A 107: 17017-17022, 2010.
95. Loot AE, Popp R, Fisslthaler B, Vriens J, Nilius B, and Fleming I. Role of cytochrome P450-dependent transient receptor potential V4 activation in flow-induced vasodilatation. Cardiovasc Res 80: 445-452, 2008.
96. Lovegrove JA and Griffin BA. The acute and long-term effects of dietary fatty acids on vascular function in health and disease. Curr Opin Clin Nutr Metab Care 16: 162-167, 2013.
97. Lu T, VanRollins M, and Lee HC. Stereospecific activation of cardiac ATP-sensitive K+ channels by epoxyeicosatrienoic acids: a structural determinant study. Mol Pharmacol 62: 1076-1083, 2002.
98. Luria A, Weldon SM, Kabcenell AK, Ingraham RH, Matera D, Jiang H, Gill R, Morisseau C, Newman JW, and Hammock BD. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem 282: 2891-2898, 2007.
99. Madanayake TW, Fidler TP, Fresquez TW, Bajaj N, and Rowland AM. Cytochrome P450 2S1 depletion enhances cell proliferation and migration in bronchial epithelial cells, in part, through modulation of prostaglandin E2synthesis. Drug Metab Dispos 40: 2119-2125, 2012.
100. Madden J, Williams CM, Calder PC, Lietz G, Miles EA, Cordell H, Mathers JC, and Minihane AM. The impact of common gene variants on the response of biomarkers of cardiovascular disease (CVD) risk to increased fish oil fatty acids intakes. Annu Rev Nutr 31: 203-234, 2011.
101. McSherry IN, Sandow SL, Campbell WB, Falck JR, Hill MA, and Dora KA. A role for heterocellular coupling and EETs in dilation of rat cremaster arteries. Microcirculation 13: 119-130, 2006.
102. Medhora M, Daniels J, Mundey K, Fisslthaler B, Busse R, Jacobs ER, and Harder DR. Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am J Physiol Heart Circ Physiol 284: H215-H224, 2003.
103. Merle BM, Benlian P, Puche N, Bassols A, Delcourt C, and Souied EH. Circulating omega-3 fatty acids and neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 55: 2010-2019, 2014.
104. Michaelis UR, Fisslthaler B, Medhora M, Harder D, Fleming I, and Busse R. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via crosstalk with the epidermal growth factor receptor (EGFR). FASEB J 17: 770-772, 2003.
105. Michaelis UR and Fleming I. From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: epoxyeicosatrienoic acids (EETs) and cell signaling. Pharmacol Ther 111: 584-595, 2006.
106. Michaelis UR, Xia N, Barbosa-Sicard E, Falck JR, Busse R, and Fleming I. Role of cytochrome P450 2C epoxygenases in hypoxia-induced cell migration and angiogenesis in retinal endothelial cells. Invest Ophthalmol Vis Sci 49: 1242-1247, 2008.
107. Moghaddam MF, Grant DF, Cheek JM, Greene JF, Williamson KC, and Hammock BD. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nat Med 3: 562-566, 1997.
108. Morin C, Sirois M, Echave V, Albadine R, and Rousseau E. 17,18-Epoxyeicosatetraenoic acid targets PPARγ and p38 mitogen-coactivated protein kinase to mediate its anti-inflammatory effects in the lung. Am J Respir Cell Mol Biol 43: 564-575, 2010.
109. Morisseau C and Hammock BD. Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu Rev Pharmacol Toxicol 53: 37-58, 2013.
110. Morisseau C, Inceoglu B, Schmelzer K, Tsai HJ, Jinks SL, Hegedus CM, and Hammock BD. Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. J Lipid Res 51: 3481-3490, 2010.
111. Muller DN, Schmidt C, Barbosa-Sicard E, Wellner M, Gross V, Hercule H, Markovic M, Honeck H, Luft FC, and Schunck WH. Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem J 403: 109-118, 2007.
112. Munzenmaier DH and Harder DR. Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release. Am J Physiol Heart Circ Physiol 278: H1163-H1167, 2000.
113. Nakamura T, Bratton DL, and Murphy RC. Analysis of epoxyeicosatrienoic and monohydroxyeicosatetraenoic acids esterified to phospholipids in human red blood cells by electrospray tandem mass spectrometry. J Mass Spectrom 32: 888-896, 1997.
114. Nakayama K, Nitto T, Inoue T, and Node K. Expression of the cytochrome P450 epoxygenase CYP2J2 in human monocytic leukocytes. Life Sci 83: 339-345, 2008.
115. Newman JW, Morisseau C, and Hammock BD. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res 44: 1-51, 2005.
116. Nguyen LN, Ma D, Shui G, Wong P, Cazenave-Gassiot A, Zhang X, Wenk MR, Goh EL, and Silver DL. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature 509: 503-506, 2014.
117. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, and Liao JK. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285: 1276-1279, 1999.
118. Node K, Ruan XL, Dai J, Yang SX, Graham L, Zeldin DC, and Liao JK. Activation of Gαs mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem 276: 15983-15989, 2001.
119. Nording ML, Yang J, Georgi K, Hegedus Karbowski C, German JB, Weiss RH, Hogg RJ, Trygg J, Hammock BD, and Zivkovic AM. Individual variation in lipidomic profiles of healthy subjects in response to omega-3 fatty acids. PLoS One 8: e76575, 2013.
120. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, and Olefsky JM. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142: 687-698, 2010.
121. Ohtoshi K, Kaneto H, Node K, Nakamura Y, Shiraiwa T, Matsuhisa M, and Yamasaki Y. Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients. Biochem Biophys Res Commun 331: 347-350, 2005.
122. Oliw EH and Benthin G. On the metabolism of epoxyeicosatrienoic acids by ram seminal vesicles: isolation of 5(6)epoxy-prostaglandin F1α. Biochem Biophys Res Commun 126: 1090-1096, 1985.
123. Ozkor MA, Murrow JR, Rahman AM, Kavtaradze N, Lin J, Manatunga A, and Quyyumi AA. Endothelium-derived hyperpolarizing factor determines resting and stimulated forearm vasodilator tone in health and in disease. Circulation 123: 2244-2253, 2011.
124. Panigrahy D, Edin ML, Lee CR, Huang S, Bielenberg DR, Butterfield CE, Barnés CM, Mammoto A, Mammoto T, Luria A, Benny O, Chaponis DM, Dudley AC, Greene ER, Vergilio JA, Pietramaggiori G, Scherer-Pietramaggiori SS, Short SM, Seth M, Lih FB, Tomer KB, Yang J, Schwendener RA, Hammock BD, Falck JR, Manthati VL, Ingber DE, Kaipainen A, D'Amore PA, Kieran MW, and Zeldin DC. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest 122: 178-191, 2012.
125. Park HS, Kim MS, Huh SH, Park J, Chung J, Kang SS, and Choi EJ. Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation. J Biol Chem 277: 2573-2578, 2002.
126. Pascual JMS, McKenzie A, Yankaskas JR, Falck JR, and Zeldin DC. Epoxygenase metabolites of arachidonic acid affect electrophysiologic properties of rat tracheal epithelial cells. J Pharmacol Exp Ther 286: 772-779, 1998.
127. Penn JS, Tolman BL, and Lowery LA. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthalmol Vis Sci 34: 576-585, 1993.
128. Pfister SL, Gauthier KM, and Campbell WB. Vascular pharmacology of epoxyeicosatrienoic acids. Adv Pharmacol 60: 27-59, 2010.
129. Popp R, Bauersachs J, Hecker M, Fleming I, and Busse R. A transferable, β-naphthoflavone-inducible, hyperpolarizing factor is synthesized by native and cultured porcine coronary endothelial cells. J Physiol (Lond) 497: 699-709, 1996.
130. Popp R, Brandes RP, Ott G, Busse R, and Fleming I. Dynamic modulation of interendothelial gap junctional communication by 11,12-epoxyeicosatrienoic acid. Circ Res 90: 800-806, 2002.
131. Potente M, Fisslthaler B, Busse R, and Fleming I. 11,12-Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27Kip1 J Biol Chem 278: 29619-29625, 2003.
132. Potente M, Michaelis UR, Fisslthaler B, Busse R, and Fleming I. Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1. J Biol Chem 277: 15671-15676, 2002.
133. Pozzi A, Macias-Perez I, Abair T, Wey S, Su Y, Zent R, Falk JR, and Capdevila JH. Charaterization of 5,6-and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J Biol Chem 280: 27138-27146, 2005.
134. Pratt PF, Li P, Hillard CJ, Kurian J, and Campbell WB. Endothelium-independent, ouabain-sensitive relaxation of bovine coronary arteries by EETs. Am J Physiol Heart Circ Physiol 280: H1113-H1121, 2001.
135. Quinlan GJ, Lamb NJ, Evans TW, and Gutteridge JM. Plasma fatty acid changes and increased lipid peroxidation in patients with adult respiratory distress syndrome. Crit Care Med 24: 241-246, 1996.
136. Rosetti C and Pastorino C. Polyunsaturated and saturated phospholipids in mixed bilayers: a study from the molecular scale to the lateral lipid organization. J Phys Chem B 115: 1002-1013, 2011.
137. Russo GL. Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochem Pharmacol 77: 937-946, 2009.
138. Samokhvalov V, Alsaleh N, El-Sikhry HE, Jamieson KL, Chen CB, Lopaschuk DG, Carter C, Light PE, Manne R, Falck JR, and Seubert JM. Epoxyeicosatrienoic acids protect cardiac cells during starvation by modulating an autophagic response. Cell Death Dis 4: e885, 2013.
139. Sandow SL and Hill CE. The incidence of myoendothelial gap junctions in the proximal and distal mesenteric arteries of the rat is suggestive of a role in EDHF mediated responses. Circ Res 86: 341-346, 2000.
140. Sandow SL, Tare M, Coleman HA, Hill CE, and Parkington HC. Involvement of myoendothelial gap junctions in the actions of endothelium-derived hyperpolarizing factor. Circ Res 90: 1108-1113, 2002.
141. Santoro N, Caprio S, Giannini C, Kim G, Kursawe R, Pierpont B, Shaw MM, and Feldstein AE. Oxidized fatty acids: a potential pathogenic link between Fatty liver and type 2 diabetes in obese adolescents? Antioxid Redox Signal 20: 383-389, 2014.
142. Sapieha P, Joyal JS, Rivera JC, Kermorvant-Duchemin E, Sennlaub F, Hardy P, Lachapelle P, and Chemtob S. Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J Clin Invest 120: 3022-3032, 2010.
143. Sapieha P, Stahl A, Chen J, Seaward MR, Willett KL, Krah NM, Dennison RJ, Connor KM, Aderman CM, Liclican E, Carughi A, Perelman D, Kanaoka Y, Sangiovanni JP, Gronert K, and Smith LE. 5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of omega-3 polyunsaturated fatty acids. Sci Transl Med 3: 69ra12, 2011.
144. Schuchardt JP, Schmidt S, Kressel G, Willenberg I, Hammock BD, Hahn A, and Schebb NH. Modulation of blood oxylipin levels by long-chain omega-3 fatty acid supplementation in hyper- and normolipidemic men. Prostaglandins Leukot Essent Fatty Acids 90: 27-37, 2014.
145. Seki H, Tani Y, and Arita M. Omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1. Prostaglandins Other Lipid Mediat 89: 126-130, 2009.
146. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510: 92-101, 2014.
147. Serhan CN and Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev 111: 5922-5943, 2011.
148. Shaikh SR. Biophysical and biochemical mechanisms by which dietary N-3 polyunsaturated fatty acids from fish oil disrupt membrane lipid rafts. J Nutr Biochem 23: 101-105, 2012.
149. Shao Z, Fu Z, Stahl A, Joyal JSb, Hatton C, Juan A, Hurst C, Evans L, Cui Z, Pei D, Gong Y, Xu D, Tian K, Bogardus H, Edin ML, Lih F, Sapieha P, Chen J, Panigrahy D, Hellstrom A, Zeldin DC, and Smith LEH. Cytochrome P450 2C8 ω3-long-chain polyunsaturated fatty acid metabolites increase mouse retinal pathologic neovascularization. Arterioscler Thromb Vasc Biol [Epub ahead of print]; DOI: 10.1161/ATVBAHA.113.302927: 2014.
150. Shivachar AC, Willoughby KA, and Ellis EF. Effect of protein kinase C modulators on 14,15-epoxyeicosatrienoic acid incorporation into astroglial phospholipids. J Neurochem 65: 338-346, 1995.
151. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, and Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275: 40504-40510, 2000.
152. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, and D'Amore PA. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35: 101-111, 1994.
153. Snyder JL, Kearns CA, and Appel B. Fbxw7 regulates Notch to control specification of neural precursors for oligodendrocyte fate. Neural Dev 7: 15, 2012.
154. Souied EH, Delcourt C, Querques G, Bassols A, Merle B, Zourdani A, Smith T, and Benlian P. Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: the nutritional AMD treatment 2 study. Ophthalmology 120: 1619-1631, 2013.
155. Spector AA and Norris AW. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 292: C996-C1012, 2007.
156. Spite M, Claria J, and Serhan CN. Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab 19: 21-36, 2014.
157. Spitzmaul G, Gumilar F, Dilger JP, and Bouzat C. The local anaesthetics proadifen and adiphenine inhibit nicotinic receptors by different molecular mechanisms. Br J Pharmacol 157: 804-817, 2009.
158. Sprong H, van der Sluijs P, and van MG. How proteins move lipids and lipids move proteins. Nat Rev Mol Cell Biol 2: 504-513, 2001.
159. Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, and Achen MG. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer 14: 159-172, 2014.
160. Taddei S, Versari D, Cipriano A, Ghiadoni L, Galetta F, Franzoni F, Magagna A, Virdis A, and Salvetti A. Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. J Am Coll Cardiol 48: 508-515, 2006.
161. Talukdar S, Olefsky JM, and Osborn O. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol Sci 32: 543-550, 2011.
162. Tikhonenko M, Lydic TA, Opreanu M, Li CS, Bozack S, McSorley KM, Sochacki AL, Faber MS, Hazra S, Duclos S, Guberski D, Reid GE, Grant MB, and Busik JV. N-3 polyunsaturated fatty acids prevent diabetic retinopathy by inhibition of retinal vascular damage and enhanced endothelial progenitor cell reparative function. PLoS One 8: e55177, 2013.
163. Ulu A, Harris TR, Morisseau C, Miyabe C, Inoue H, Schuster G, Dong H, Iosif AM, Liu JY, Weiss RH, Chiamvimonvat N, Imig JD, and Hammock BD. Anti-inflammatory effects of omega-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. J Cardiovasc Pharmacol 62: 285-297, 2013.
164. Urano Y, Hayashi I, Isoo N, Reid PC, Shibasaki Y, Noguchi N, Tomita T, Iwatsubo T, Hamakubo T, and Kodama T. Association of active gamma-secretase complex with lipid rafts. J Lipid Res 46: 904-912, 2005.
165. VanRollins M, Kaduce TL, Fang X, Knapp HR, and Spector AA. Arachidonic acid diols produced by cytochrome P-450 monooxygenases are incorporated into phospholipids of vascular endothelial cells. J Biol Chem 271: 14001-14009, 1996.
166. Virdis A, Cetani F, Giannarelli C, Banti C, Ghiadoni L, Ambrogini E, Carrara D, Pinchera A, Taddei S, Bernini G, and Marcocci C. The sulfaphenazole-sensitive pathway acts as a compensatory mechanism for impaired nitric oxide availability in patients with primary hyperparathyroidism. Effect of surgical treatment. J Clin Endocrinol Metab 95: 920-927, 2010.
167. Vriens J, Owsianik G, Fisslthaler B, Suzuki M, Janssens A, Voets T, Morisseau C, Hammock BD, Fleming I, Busse R, and Nilius B. Modulation of the Ca2+ permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res 97: 908-915, 2005.
168. Wada M, DeLong CJ, Hong YH, Rieke CJ, Song I, Sidhu RS, Yuan C, Warnock M, Schmaier AH, Yokoyama C, Smyth EM, Wilson SJ, FitzGerald GA, Garavito RM, Sui DX, Regan JW, and Smith WL. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem 282: 22254-22266, 2007.
169. Wang MH, Brand-Schieber E, Zand BA, Nguyen X, Falck JR, Balu N, and Schwartzman ML. Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J Pharmacol Exp Ther 284: 966-973, 1998.
170. Wang RX, Chai Q, Lu T, and Lee HC. Activation of vascular BK channels by docosahexaenoic acid is dependent on cytochrome P450 epoxygenase activity. Cardiovasc Res 90: 344-352, 2011.
171. Wang X, Ni L, Yang L, Duan Q, Chen C, Edin ML, Zeldin DC, and Wang DW. CYP2J2-derived epoxyeicosatrienoic acids suppress endoplasmic reticulum stress in heart failure. Mol Pharmacol 85: 105-115, 2014.
172. Wang Y, Wei X, Xiao X, Hui R, Card JW, Carey MA, Wang DW, and Zeldin DC. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther 314: 522-532, 2005.
173. Wassall SR and Stillwell W. Docosahexaenoic acid domains: the ultimate non-raft membrane domain. Chem Phys Lipids 153: 57-63, 2008.
174. Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, and Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 424: 434-438, 2003.
175. Webler AC, Popp R, Korff T, Michaelis UR, Urbich C, Busse R, and Fleming I. Cytochrome P450 2C9-induced angiogenesis is dependent on EphB4. Arterioscler Thromb Vasc Biol 28: 1123-1129, 2008.
176. Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P, and Spector AA. Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ Res 81: 258-267, 1997.
177. Westphal C, Konkel A, and Schunck WH. CYP-eicosanoids - a new link between omega-3 fatty acids and cardiac disease? Prostaglandins Other Lipid Mediat 96: 99-108, 2011.
178. Wiecha J, Munz B, Wu Y, Noll T, Tillmanns H, and Waldecker B. Blockade of Ca2+-activated K+ channels inhibits proliferation of human endothelial cells induced by basic fibroblast growth factor. J Vasc Res 35: 363-371, 1998.
179. Wiley DM, Kim JD, Hao J, Hong CC, Bautch VL, and Jin SW. Distinct signalling pathways regulate sprouting angiogenesis from the dorsal aorta and the axial vein. Nat Cell Biol 13: 686-692, 2011.
180. Williams JA, Batten SE, Harris M, Rockett BD, Shaikh SR, Stillwell W, and Wassall SR. Docosahexaenoic and eicosapentaenoic acids segregate differently between raft and nonraft domains. Biophys J 103: 228-237, 2012.
181. Wray J and Bishop-Bailey D. Epoxygenases and peroxisome proliferator-activated receptors in mammalian vascular biology. Exp Physiol 93: 148-154, 2008.
182. Wray JA, Sugden MC, Zeldin DC, Greenwood GK, Samsuddin S, Miller-Degraff L, Bradbury JA, Holness MJ, Warner TD, and Bishop-Bailey D. The epoxygenases CYP2J2 activates the nuclear receptor PPARα in vitro and in vivo. PLoS One 4: e7421, 2009.
183. Yamada T, Morisseau C, Maxwell JE, Argiriadi MA, Christianson DW, and Hammock BD. Biochemical evidence for the involvement of tyrosine in epoxide activation during the catalytic cycle of epoxide hydrolase. J Biol Chem 275: 23082-23088, 2000.
184. Yang W, Tuniki VR, Anjaiah S, Falck JR, Hillard CJ, and Campbell WB. Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-125I-14,15-epoxyeicosa-8(Z)-enoic acid. J Pharmacol Exp Ther 324: 1019-1027, 2008.
185. Ye D, Zhang D, Oltman C, Dellsperger K, Lee HC, and VanRollins M. Cytochrome p-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels. J Pharmacol Exp Ther 303: 768-776, 2002.
186. Ye D, Zhou W, and Lee HC. Activation of rat mesenteric arterial KATP channels by 11,12-epoxyeicosatrienoic acid. Am J Physiol Heart Circ Physiol 288: H358-H364, 2005.
187. Ye D, Zhou W, Lu T, Jagadeesh SG, Falck JR, and Lee HC. Mechanism of rat mesenteric arterial KATP channel activation by 14,15-epoxyeicosatrienoic acid. Am J Physiol Heart Circ Physiol 290: H1326-H1336, 2006.
188. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, Zeldin DC, and Kroetz DL. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 87: 992-998, 2000.
189. Zech T, Ejsing CS, Gaus K, de WB, Shevchenko A, Simons K, and Harder T. Accumulation of raft lipids in T-cell plasma membrane domains engaged in TCR signalling. EMBO J 28: 466-476, 2009.
190. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276: 36059-36062, 2001.
191. Zemski Berry KA, Gordon WC, Murphy RC, and Bazan NG. Spatial organization of lipids in the human retina and optic nerve by MALDI imaging mass spectrometry. J Lipid Res 55: 504-515, 2014.
192. Zhang C and Harder DR. Cerebral capillary endothelial cell mitogenesis and morphogenesis induced by astrocytic epoxyeicosatrienoic acid. Stroke 33: 2957-2964, 2002.
193. Zhang G, Panigrahy D, Mahakian LM, Yang J, Liu JY, Stephen Lee KS, Wettersten HI, Ulu A, Hu X, Tam S, Hwang SH, Ingham ES, Kieran MW, Weiss RH, Ferrara KW, and Hammock BD. Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A 110: 6530-6535, 2013.
194. Zhang Y, Oltman CL, Lu T, Lee HC, Dellsperger KC, and VanRollins M. EET homologs potently dilate coronary microvessels and activate BK(Ca) channels. Am J Physiol Heart Circ Physiol 280: H2430-H2440, 2001.
195. Zhao G, Wang J, Xu X, Jing Y, Tu L, Li X, Chen C, Cianflone K, Wang P, Dackor RT, Zeldin DC, and Wang DW. Epoxyeicosatrienoic acids protect rat hearts against tumor necrosis factor-α-induced injury. J Lipid Res 53: 456-466, 2012.
196. Zheng X, Zinkevich NS, Gebremedhin D, Gauthier KM, Nishijima Y, Fang J, Wilcox DA, Campbell WB, Gutterman DD, and Zhang DX. Arachidonic acid-induced dilation in human coronary arterioles: convergence of signaling mechanisms on endothelial TRPV4-mediated Ca2+ entry. J Am Heart Assoc 2: e000080, 2013.
197. Zhu Y, Schieber EB, McGiff JC, and Balazy M. Identification of arachidonate P-450 metabolites in human platelet phospholipids. Hypertension 25: 854-859, 1995.
198. Zou AP, Fleming JT, Falck JR, Jacobs ER, Gebremedhin D, Harder DR, and Roman RJ. Stereospecific effects of epoxyeicosatrienoic acids on renal vascular tone and K+- channel activity. Am J Physiol Renal Physiol 270: F822-F832, 1996.
199. Zygmunt PM and Högestätt ED. Role of potassium channels in endothelium-dependent relaxation resistant to nitroarginine in the rat hepatic artery. Br J Pharmacol 117: 1600-1606, 1996.